Scipher Medicine Previews Precision Rheumatoid Arthritis Test
The company announces an early access program for a blood-based test designed to predict patient response to abatacept.
Updated on Oct. 28, 2026 in Arthritis
Live Poll
Do you believe personalized genetic testing helps patients find the most effective medical treatments?
Scipher Medicine has introduced an early access program for its PrismTcell blood test, which identifies molecular signatures to predict how rheumatoid arthritis patients will respond to the drug abatacept. The announcement follows findings that patients guided by the test reached a higher response rate in clinical trials.
Why it matters
The test aims to help physicians identify which patients are likely to respond to abatacept before beginning treatment, potentially reducing time spent on ineffective therapies. This targeted approach seeks to improve clinical outcomes for those living with rheumatoid arthritis.
Participants in the PREDICT study, which spanned 40 clinical sites across the U.S., achieved a 2-fold higher ACR50 response rate when using the diagnostic tool. The test is processed in a CLIA-certified and CAP-accredited laboratory.
The players
Scipher Medicine
This biotechnology company focuses on developing molecular diagnostic tests and precision therapies to improve patient outcomes.
The details
Physicians can use the test to analyze transcriptomic profiles and SNP genotyping from blood samples to determine if a patient is a candidate for abatacept. The development marks the company's entry into the precision therapeutics market.
Timeline
October 28, 2026: Scipher Medicine announced the PrismTcell early access program.
November 10, 2026: The company will present data at ACR Convergence 2026.
Q1 2027: Scipher Medicine plans to launch the PrismTcell Early Access Program.
Health Landscape
The development of the PrismTcell test follows the methodology established by the PREDICT study. This diagnostic tool represents a significant shift toward precision medicine, allowing for more personalized treatment pathways in rheumatology.
The test provides adult patients with a method to determine the efficacy of abatacept before starting the medication. This could streamline the treatment process and help patients avoid the side effects of drugs that are ultimately ineffective for their condition.
The takeaway
Precision diagnostics represent a growing effort to reduce the trial-and-error process often associated with prescribing biologic therapies for chronic conditions. Patients should consult with their rheumatologist to discuss whether biomarker testing is a suitable part of their treatment plan.
What happens next
The PrismTcell Early Access Program is scheduled to launch in early Q1 2027.
Further reading
Learn more about new diagnostic advancements in Arthritis.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe personalized genetic testing helps patients find the most effective medical treatments?
